Treatment guidelines for CAR T-cell therapy

Print Friendly, PDF & Email


CAR T cells
Photo from Penn Medicine
Researchers have developed treatment guidelines for pediatric patients receiving chimeric antigen receptor (CAR) T-cell therapy. The guidelines include recommendations for patient selection and consent, treatment details, and advice on managing cytokine release syndrome (CRS) and other adverse events associated with CAR T-cell therapy. The guidelines were published in... [Read Article]
Print Friendly, PDF & Email

Adult CCSs report financial hardships

Print Friendly, PDF & Email


I-Chan Huang, PhD
Photo from St. Jude
Children’s Research
Hospital/Peter Barta
Health-related financial hardship is common among adult survivors of childhood cancer, according to a study published in the Journal of the National Cancer Institute. Researchers analyzed more than 2800 long-term childhood cancer survivors (CCSs) and found that 65% had financial challenges related to their... [Read Article]
Print Friendly, PDF & Email

CHMP announces 2 opinions on blinatumomab

Print Friendly, PDF & Email


Vials of blinatumomab
powder and solution
Photo courtesy of Amgen
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has released 2 new opinions regarding blinatumomab (Blincyto). The CHMP recommended expanding the approved use of blinatumomab to include pediatric patients, but the committee also recommended against approving blinatumomab to treat patients with... [Read Article]
Print Friendly, PDF & Email

Treatments, disease affect spermatogonia in boys

Print Friendly, PDF & Email


Male germinal epithelium
showing spermatogonia,
spermatocytes, spermatids,
and spermatozoa
Image from Dreamstime
Alkylating agents, hydroxyurea (HU), and certain non-malignant diseases can significantly deplete spermatogonial cell counts in young boys, according to research published in Human Reproduction. Boys who received alkylating agents to treat cancer had significantly lower spermatogonial cell counts than control subjects or boys... [Read Article]
Print Friendly, PDF & Email

Study suggests dasatinib could treat AML, JMML

Print Friendly, PDF & Email


Micrograph showing JMML
© Universitätsklinikum Freiburg
New research suggests dasatinib could treat certain patients with juvenile myelomonocytic leukemia (JMML) or acute myeloid leukemia (AML). The study showed that TNK2 inhibition has a negative effect on PTPN11-mutant leukemias. PTPN11-mutant JMML and AML cells were sensitive to treatment with dasatinib, which inhibits TNK2. Dasatinib also induced hematologic... [Read Article]
Print Friendly, PDF & Email

Mutations linked to higher risk of SNs in CCSs

Print Friendly, PDF & Email


Pediatric cancer patient
with St. Jude doctors
Photo from Seth Dixon,
St. Jude Children’s
Research Hospital
New research has shown that childhood cancer survivors (CCSs) with certain germline mutations have higher relative rates (RRs) of secondary neoplasms (SNs) later in life. Mutation carriers had significantly higher rates of breast cancer and sarcoma if they had... [Read Article]
Print Friendly, PDF & Email

Mircera approved for anemia in pediatric patients with CKD

Print Friendly, PDF & Email


Red blood cells
Mircera®, methoxy polyethylene glycol-epoetin beta, was approved by the US Food and Drug Administration (FDA) to treat anemia in pediatric patients who have chronic kidney disease (CKD). The drug is indicated for patients ages 5 to 17 years on hemodialysis who are switching from another erythropoiesis-stimulating agent (ESA) after their hemoglobin levels... [Read Article]
Print Friendly, PDF & Email

Dasatinib outcomes similar to imatinib in pediatric Ph+ ALL

Print Friendly, PDF & Email


Child with leukemia
Photo by Bill Branson
Dasatinib used during induction and consolidation in the Children’s Oncology Group (COG) AALL0622 trial provided early response rates for children with Ph-positive (Ph+) acute lymphoblastic leukemia (ALL), according to investigators. But the early response rates did not improve event-free survival (EFS) compared to the use of consolidation... [Read Article]
Print Friendly, PDF & Email

VF incidence increases significantly in kids after ALL treatment

Print Friendly, PDF & Email


Lumbar vertebrae (shown in red)
Credit: Anatomography
A 6-year prospective study from the Canadian STOPP investigators revealed that following treatment for acute lymphoblastic leukemia (ALL), approximately 1 out of 3 children experiences vertebral fractures (VF) and 1 out of 5 children shows non-VF. Glucocorticoid use and vertebral fractures at diagnosis emerged as significant... [Read Article]
Print Friendly, PDF & Email

Early infection could prevent ALL, doc says

Print Friendly, PDF & Email


Smiling baby
Photo by Petr Kratochvil
Childhood acute lymphoblastic leukemia (ALL) may be preventable, according to a researcher. Mel Greaves, PhD, of The Institute of Cancer Research in London, UK, has reviewed more than 30 years of research and concluded that ALL develops in 2 steps—genetic mutation before birth and further genetic change... [Read Article]
Print Friendly, PDF & Email

Regimen can improve DFS in newly diagnosed T-ALL

Print Friendly, PDF & Email


Vials of drugs
Photo by Bill Branson
The addition of nelarabine can improve treatment outcomes for certain patients with T-cell acute lymphoblastic leukemia (T-ALL), according to a phase 3 trial. Patients with newly diagnosed, intermediate- or high-risk T-ALL had a significant improvement in 4-year disease-free survival (DFS) if they received nelarabine in addition to chemotherapy... [Read Article]
Print Friendly, PDF & Email

MSC product can treat refractory GVHD

Print Friendly, PDF & Email


Mesenchymal stem cells
Results from a phase 3 trial suggest a mesenchymal stem cell (MSC) product can treat steroid-refractory, acute graft-versus-host disease (GVHD) in children. The product, remestemcel-L (MSC-100-IV), produced an overall response rate of 69% at day 28, with complete resolution of GVHD in 29% of patients. Adverse events (AEs) in this trial... [Read Article]
Print Friendly, PDF & Email

CHMP backs approval of dasatinib for kids

Print Friendly, PDF & Email


CML cells
Image by Difu Wu
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended changes to the marketing authorization for dasatinib (Sprycel). The CHMP is recommending approval for dasatinib as a treatment for pediatric patients with newly diagnosed, Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase... [Read Article]
Print Friendly, PDF & Email